Related Experiment Video
Updated: May 24, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Drug studies in newborns: a therapeutic imperative
George P Giacoia1, Perdita Taylor-Zapata, Anne Zajicek
1Obstetric and Pediatric Pharmacology Branch; Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6100 Executive Boulevard,Rockville, MD 20852, USA. giacoiag@mail.nih.gov
Abstract:
Although some drugs have been developed for the neonate, drug development for the least mature and most vulnerable pediatric patients is lacking. Most of the drugs are off-label or off-patent and are empirically administered to newborns once efficacy has been demonstrated in adults and usefulness is suspected or demonstrated in the older pediatric population. Few drugs are approved by the Food and Drug Administration for use in this population. The factors that prevent the demonstration of efficacy and safety in the newborn are discussed and a change in the current approach for neonatal drug studies is suggested.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Factors Affecting Drug Response: Overview
